ACTRN12610000506099终止2 期
Women over 18 years with Triple Negative (oestrogen receptor alpha negative, progesterone receptor negative, HER-2 negative) but Oestrogen Receptor Beta Positive Metastatic Breast Cancer will be treated with Tamoxifen to assess the efficacy of this treatment
Australia and New Zealand Breast Cancer Trials Group0 个研究点目标入组 5 人开始时间: 2010年6月18日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- Female
入选标准
- •1. Female patients, greater than or equal to 18 years with histologically or cytologically confirmed triple negative (oestrogen receptor alpha (ERa) absent, PgR (progesterone receptor) absent, Human Epidermal growth factor Receptor 2 (HER2) In situ hybridisaton (ISH) negative or immunohistochemistry ((IHC) 0 or 1)) breast cancer. All IHC results for ERa and PgR on all tumour specimens must not show any staining in the tumour (i.e. ERa and PgR absent staining in all tumour specimens). 2. Metastatic disease for which, in the investigator’s opinion, chemotherapy and/or radiotherapy is currently not indicated. 3. Metastatic disease amenable to biopsy or previously biopsied. All patients must have a biopsy from a metastatic disease site, including patients presenting with de novo metastatic disease. A biopsy from axillary or supraclavicular nodes is acceptable for the following: a) Patients with no distant metastatic disease but with axillary or supraclavicular nodal disease that is considered incurable, either: i) Axillary nodes (ipsilateral or contralateral), that are measurable by RECIST and can be followed for response ii) Supraclavicular nodes (ipsilateral or contralateral) that are measurable by RECIST and can be followed for response. b) Patients with distant metastatic disease which is not amenable to biopsy Note that for a) part i) and b) the biopsy confirming triple negative, ER beta positive breast cancer in the axillary node must have occurred at a time point when the disease was considered incurable, i.e. the original pathology from initial sentinel node biopsy or axillary dissection undertaken as part of curative therapy is NOT acceptable. 4. ER beta positive in the metastatic breast cancer sample. (ERbeta1 will be measured with IHC and nuclear ERbeta1 staining with Allred score >3 defined as positive). 5. At least one measurable lesion as defined by revised Response Evaluation Criteria in Solid Tumours 1.1 (RECIST) (at least one lesion that can be accurately measured in at least one dimension with longest diameter to be recorded as greater than or equal to 20 mm with conventional techniques or as greater than or equal to 10 mm with spiral computed tomography (CT scan). Measurable lesions in a previously irradiated field are excluded unless progression in the lesion post radiotherapy is documented according to RECIST criteria on the CT scan. 6. At the time of registration, patients must fulfill one of the following: a) Disease is currently progressing - last administration of systemic anti-cancer therapy for metastatic disease (if given) must have ceased greater than or equal to 21 days prior to registration. OR b) Disease is currently not progressing - last administration of systemic anti-cancer therapy for metastatic disease (if given) must have ceased greater than or equal to 42 days prior to registration. 7. Life expectancy of 12 weeks or more. 8. Eastern cooperative oncology group (ECOG)performance status less than or equal to 2. 9. Provision of written informed consent.
排除标准
- •1.Patients with any positive staining for ERa and/or PgR in ANY sample of invasive breast cancer (including any biopsy of earlier stage disease).
- •2.Rapidly progressive metastatic disease which, in the investigator’s opinion is not suitable for endocrine therapy.
- •3.Last dose of chemotherapy < 21 days before the start of tamoxifen. Patients must not have concurrent chemotherapy and tamoxifen.
- •4.Treatment with an investigational drug < 21 days prior to registration.
- •5.Only measurable lesions in a previously irradiated field without evidence of progression.
- •6.Patients who have had previous hormonal therapy for breast cancer (includes Selective Oestrogen Receptor Modulators and Aromatase Inhibitors).
- •7.Newly diagnosed or uncontrolled intracerebral metastases. Previously treated, asymptomatic brain metastases are permissible; patients must be stable and off steroid therapy and have a life expectancy of at least 12 weeks.
- •8.History of allergic reactions attributed to compounds of similar chemical or biologic composition to tamoxifen.
- •9.Receiving any medications or substances that are inhibitors or inducers of CYP3A4 and CYP2D6.
- •10.Previous or concomitant invasive malignancy (except breast cancer). The exceptions are:
- •a)patients with non-breast malignancy greater than or equal to10 years ago, treated with curative intent and without evidence of recurrence
- •b)basal or squamous cell carcinoma of the skin
- •c)in situ carcinoma without invasion (includes in situ breast carcinoma)
- •d)the following non-breast invasive malignancy diagnosed greater than or equal to 5 years ago and without recurrence:
- •i) stage I papillary thyroid cancer
- •ii)stage Ia carcinoma of the cervix
- •iii) borderline or stage I ovarian cancer
- •iv) superficial bladder cancer
- •11.Psychiatric illness/social situations that would limit compliance with study requirements.
- •12.Pregnancy or breast feeding (women of child-bearing potential must agree to use adequate non-hormonal contraception). A serum or urine test must be carried out on all women of child-bearing potential to exclude pregnancy.
- •13.Patients with a history of thrombosis should only participate if considered medically suitable by their doctor.
研究者
相似试验
已完成
3 期
IBCSG 35-07 / BIG 1-07 : Study of Letrozole Extension (SOLE). Letrozole in Preventing the Return of Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer.Endocrine Responsive Breast CancerCancer - BreastACTRN12608000243314ovartis Pharma AG4,800
招募中
不适用
A randomised control trial on the effect of a herbal product, 30Plus, on mood swings and anxiety in younger womeMild to moderate depression and anxietyAlternative and Complementary Medicine - Herbal remediesACTRN12609000015246atural Health Products Pty Ltd110
进行中（未招募）
4 期
The effect of the drug resiniferatoxin on the bladder as a treatment for cases of incontinence previously unresponsive to treatment.Refractory idiopathic detrusor overactivityRenal and Urogenital - Other renal and urogenital disordersOther - Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)ACTRN12612000598886Pelvic Floor Unit Research Fund (St George Hospital)50
尚未招募
不适用
Hormonal changes in women with excessive bleeding following delivery.CTRI/2020/07/026653Maulana Azad Medical College
招募中
不适用
THE IMPORTANCE OF ANTIMULLERIAN HORMONE IN DIAGNOSIS OF POLYCYSTIC OVARIAN SYNDROMECTRI/2017/02/007800Sanjay Gandhi Postgraduate Institute of medical Sciences280